Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension , today announced...

Related Keywords

Bob Smith ,Nasdaq ,Compensation Committee Of Gossamer Board Directors ,Gossamer Bio Inc ,Gossamer Bio ,Chief Commercial ,Compensation Committee ,Inducement Incentive Award Plan ,Nasdaq Listing Rule ,Nasdaq Global Select Market ,Markets ,